Northstrive Biosciences Inc., a Subsidiary of PMGC Holdings Inc., Signs Agreement For Preclinical Mouse Study of EL-32, a Potential Breakthrough Obesity Therapy Targeting Fat Loss and Muscle Preservation in Combination with GLP-1
January 30, 2025 08:00 ET
|
PMGC Holdings Inc.
Northstrive Biosciences Inc., a Subsidiary of PMGC Holdings Inc., Signs Agreement For Preclinical Mouse Study of EL-32, a Potential Breakthrough Obesity Th
Northstrive Biosciences Inc., a Subsidiary of PMGC Holdings Inc., to Present Breakthrough Muscle Preservation Asset at Exclusive UCLA Obesity Symposium
January 24, 2025 08:00 ET
|
PMGC Holdings Inc.
Northstrive Biosciences Inc., a Subsidiary of PMGC Holdings Inc., to Present Breakthrough Muscle Preservation Asset at Exclusive UCLA Obesity Symposium
Digbi Health Expands its Multi-Condition Care Platform to Enhance Efficacy and Adherence to GLP-1 Drugs
January 17, 2025 05:21 ET
|
Digbi Health
PALO ALTO, Calif., Jan. 17, 2025 (GLOBE NEWSWIRE) -- Digbi Health, a pioneer in Precision Biology, is advancing obesity management with groundbreaking enhancements to GLP-Compass (™), its...
Tiziana Announces Reduction of Side Effects Commonly Seen with Discontinuation of GLP-1 Agonists with Nasal Anti-CD3
January 10, 2025 08:00 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
Americans Weigh In: International Food Information Council Releases New Research Examining Perceptions Around Obesity & Weight Loss Medications
January 08, 2025 11:23 ET
|
International Food Information Council Foundation
Washington, DC, Jan. 08, 2025 (GLOBE NEWSWIRE) -- The International Food Information Council (IFIC) has published a new survey examining Americans’ attitudes and perceptions toward obesity...
Semaglutides Market Research Report 2024-2028 & 2033 Featuring Major Players, Pfizer, Roche, Merck, AbbVie, and Sanofi
January 06, 2025 04:12 ET
|
Research and Markets
Dublin, Jan. 06, 2025 (GLOBE NEWSWIRE) -- The "Semaglutides Market Report 2024" report has been added to ResearchAndMarkets.com's offering.This Semaglutides market report covers market...
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Announces FDA Regulatory Pathway for EL-22, a Pioneering Obesity Therapy Targeting Fat Loss and Muscle Preservation
December 09, 2024 08:00 ET
|
Elevai Labs Inc.
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Announces FDA Regulatory Pathway for EL-22, a Pioneering Obesity Therapy Targeting Fat Loss and Muscl
CORRECTION - Elevai Labs Inc.
November 14, 2024 14:35 ET
|
Elevai Labs Inc.
/CORRECTION/ Elevai Labs Inc. Reports Financial Results for the Third Fiscal Quarter of 2024 and Provides Business Update
Elevai Labs Inc. Reports Financial Results for the Second Fiscal Quarter of 2024 and Provides Business Update
November 14, 2024 09:08 ET
|
Elevai Labs Inc.
Elevai Labs Inc. Reports Financial Results for the Second Fiscal Quarter of 2024 and Provides Business Update
Tiziana Life Sciences Announces Positive Results from Ozempic and Nasal Anti-CD3 Combination Study
October 30, 2024 08:30 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...